TOV-2978G cell line

Cat. #161779

TOV-2978G cell line

Cat. #: 161779

Organism: Human

Tissue: Derived from high-grade serous tumors


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941

Tool Details

Tool Details


  • Name: TOV-2978G cell line
  • Alternate name: TOV-2978G
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from high-grade serous tumors
  • Donor: Age of diagnosis: 63; BRCA hereditary status: negative; Grade 3 – Stage IIIC; Mutations: TP53; Pre-treatment
  • Morphology: Small epithelial type cells. Formed individual small aggregates
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors of patient who was chemotherapy naive at time of sampling. Results show that the intronic TP53 mutation seems to also affect transcription since neither mRNA nor protein were detected in this cel lline
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 2978 was age 63 at diagnosis with BRCA hereditary status as negative. Patient was chemotherapy naive at sample collection. First line treatment involved surgery, Carboplatin, and taxol. There was no previous personal history of cancer nor prior oncologic treatment. The year of sampling was 2006.


  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin


  • Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
  • 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
  • 15(9):2566. PMID: 37174032